Comparative Pharmacology
Head-to-head clinical analysis: PREMPRO versus STILPHOSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREMPRO versus STILPHOSTROL.
PREMPRO vs STILPHOSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PREMPRO is a combination of conjugated estrogens and medroxyprogesterone acetate. Estrogens bind to estrogen receptors, activating gene transcription and exerting effects on various tissues. Medroxyprogesterone acetate is a progestin that suppresses endometrial proliferation, reducing the risk of endometrial hyperplasia associated with unopposed estrogen therapy.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
One tablet orally once daily; each tablet contains conjugated estrogens 0.625 mg and medroxyprogesterone acetate 2.5 mg or 5 mg.
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
None Documented
None Documented
The terminal elimination half-life of conjugated estrogens (primarily estrone and equilin) ranges from 10-24 hours (mean ~15 hours) after oral administration. This supports once-daily dosing with steady-state achieved within 5-7 days.
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Conjugated estrogens are primarily excreted in urine (renal elimination accounts for ~50-80% of total clearance) as glucuronide and sulfate conjugates. A smaller fraction undergoes biliary excretion (~10-20%) and is eliminated in feces via enterohepatic circulation.
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Category C
Category C
Estrogen/Progestin Combination
Estrogen